Viracta Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Viracta Therapeutics reports a net loss of $10.55 million for the third quarter of 2024 and provides an update on its clinical programs, including a strategic shift to focus on lymphoma.
Viracta Therapeutics announced a strategic shift to prioritize its lymphoma program, pausing its solid tumor program, while also reporting its financial results for the second quarter of 2024.
Viracta Therapeutics reports a net loss of $9.1 million for the first quarter of 2024, while advancing its clinical programs for Nana-val.